There is the question of reimbursement (patients OOP costs vs. lupron where urologists are making money). Curious that AbbVie did not pursue this indication for elagolix.
re: MYOV’s Orgovyx (relugolix) for prostate cancer, thank you, and do not wish to diminish the progress of that drug, just wish "they" ( all the ones doing other stuff) would open up the real gun cabinet with live effective bullets, as lag time has been decades for this field, while Covid-19 science has introduced me to think in terms of warp speed, to contain miseries like prostate cancer once and for all!
Market Data 
Markets 
AI
